Updated: Oct 20
Medically reviewed by ChinaCureLink Team
Table of Content
Introduction
Patients who have undergone allogeneic hematopoietic stem cell transplantation may encounter mesenchymal stem cell (MSC) therapy as an approach being explored for complications requiring immune modulation. In China, this therapy is available through the supervised Boao Lecheng pilot-zone pathway as part of the second batch of approved projects. This guide explains what the treatment is, who may be considered, its estimated cost, and what international patients should know before pursuing it.
Key Takeaways |
|
Is Transplant Complications Stem Cell Therapy China Available?
Mesenchymal stem cell therapy uses mesenchymal stem cells as immune-modulating cells rather than as replacement cells for the patient's transplanted bone marrow or blood-forming cells.
For this treatment, MSCs from sources that may include bone marrow or umbilical cord are administered through intravenous reinfusion. The treatment approach described for this program is intended to provide immune modulation following allogeneic hematopoietic stem cell transplantation.
For patients researching transplant complications stem cell therapy China, the relevant access pathway is currently the Boao Lecheng pilot zone in Hainan rather than nationwide availability
The available treatment information does not establish a specific clinical outcome or cure. The appropriateness of MSC therapy depends on the patient's transplant history, current condition, and assessment by the treating medical team.
Is Mesenchymal Stem Cell Therapy Available in China?
Yes. This MSC therapy is available through the Boao Lecheng International Medical Tourism Pilot Zone in Hainan, where it is included in the second batch of approved projects and has a registration date of 2025.
This is a supervised pilot-zone access pathway rather than nationwide approval for routine use throughout China. Patients therefore need to be assessed through the designated medical provider, and access remains subject to professional review and eligibility requirements.
Pilot-zone inclusion establishes an access pathway within the designated program; it should not be interpreted as nationwide regulatory approval or proof of treatment effectiveness.
Where Is the Treatment Offered?
The treatment is offered at Hainan Haikong Le City Hospital (West China Le City Hospital of Sichuan University) in Hainan.
Technical support is provided by Qingdao Huasheng Shida Biopharmaceutical Co., Ltd.
The treatment method is intravenous reinfusion of MSCs, with cell sources including bone marrow and umbilical cord.
Who May Be Eligible?
Eligibility is for patients who have undergone an allogeneic hematopoietic stem cell transplant and are assessed as suitable candidates for immunomodulation by a professional care team.
The patient's medical history, transplant status, current complications, and overall clinical circumstances need to be reviewed by the treating team. Patients cannot determine their own eligibility based on the general criteria alone.
Final eligibility is determined by the treating medical team after a face-to-face consultation or review of the patient's medical records.
How Much Does It Cost?
The estimated cost is ¥80,000 (approximately US$11,900) per session. The USD estimate uses a USD/CNY exchange rate of about 6.72 yuan per US dollar; exchange rates can change.
The stated treatment price does not necessarily include consultation, diagnostic testing, hospitalization, translation or coordination services, or travel expenses. Patients should confirm the full scope of the quoted price and final pricing directly with the hospital before making travel arrangements.
Why International Patients May Consider This Option
For some international patients who have undergone an allogeneic hematopoietic stem cell transplant, access to an MSC-based immune-modulation approach may be worth discussing with a qualified specialist when additional management is being considered.
The Boao Lecheng pathway provides a supervised route to explore this treatment in a designated hospital in China. However, pilot-zone availability does not establish that MSC therapy is superior to established management approaches, and patients should evaluate potential benefits, risks, alternatives, and eligibility with their treating physicians.
How ChinaCureLink Can Help Patients Access This Treatment
We help international patients explore available treatment options and facilitate communication with appropriate medical specialists. Patients should discuss potential benefits, risks, eligibility, and alternatives directly with qualified physicians. ChinaCureLink does not represent or endorse the treatment technology, manufacturer, or hospital.
Case review: We collect relevant medical history and bone marrow transplant complications-management records to help determine whether a case is appropriate for physician review.
Hospital coordination: We help connect patients with the treating team at Hainan Haikong Le City Hospital (West China Le City Hospital of Sichuan University) in China for an initial assessment.
Online consultation before travel: Patients can discuss potential eligibility, the procedure, and expected next steps with the medical team remotely before committing to international travel.
Coordination support: Depending on the case, this can include translation assistance, appointment scheduling, and logistics coordination.
Considering This Treatment in China?
Before planning travel, speak with a qualified specialist to determine whether the treatment is appropriate for your condition and whether you meet the medical eligibility requirements. ChinaCureLink can help international patients arrange a specialist review and explore the treatment pathway in China. Request a Medical Review / Speak With a Specialist
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
★★★★☆ Pongsakorn · Thailand · Feb 2025 · Verified “Kiki at Medebound is amazing — so professional and helpful! They got my video consultation with an MD Anderson expert set up super fast, within just 5 working days. I am so grateful for their support.” |
Frequently Asked Questions
Is mesenchymal stem cell therapy available in China after a bone marrow transplant?
Yes. This MSC therapy is available through the Boao Lecheng pilot-zone pathway in Hainan at Hainan Haikong Le City Hospital, subject to professional medical assessment.
How much does MSC therapy cost in China?
The estimated cost is approximately US$11,900, per session. Patients should confirm final pricing and what the treatment fee covers directly with the hospital.
Who may be eligible for MSC therapy after an allogeneic stem cell transplant?
Patients who have undergone an allogeneic hematopoietic stem cell transplant and are assessed by a professional care team as suitable candidates for immunomodulation may be considered.
Can international patients access this treatment in Hainan?
International patients may explore access through the designated Hainan Boao Lecheng pathway, but treatment requires medical assessment and confirmation of eligibility before travel.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
